Our Team

Our leaders are passionate, empowered and committed to our mission to make a difference in the lives of patients.

Leadership Team

  • Jeff Jonas joined Sage as CEO in 2013, bringing with him more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, with a focus on central nervous system disorders. At Sage, he’s created an engine of innovation that encourages creating new opportunities by taking smart risks and challenging conventional wisdom. Jeff’s approach is shaped by a career that encompasses one-on-one patient care, rapid advancement through corporate structures, academic accomplishments, and entrepreneurial endeavors. Before joining the Sage team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff is a member of the board for Decibel Therapeutics, Generation Bio and Karuna Pharmaceuticals. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts and has received numerous awards.

    Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

  • Mike is the architect of the Sage commercial organization that is preparing for full product promotion. He joined Sage as Chief Business Officer in April 2017 and leads the Commercial, Portfolio and Program Management, Medical Affairs, and Corporate Development departments. Previously, he served as Senior Vice President, US Commercial, at Biogen where he led the US affiliate with direct general manager responsibility for Sales, Marketing, Market Access, Patient Services and Commercial Operations. Mike’s 14-year tenure at Biogen included roles as Senior Vice President, Global Commercial Strategy; Vice President, Managing Director, Australia/New Zealand affiliate; and Vice President, Business Planning. Prior to Biogen, he worked at Bain & Company as a consultant specializing in healthcare.

    Mike earned his M.B.A. from Darden Graduate School of Business Administration, University of Virginia and a B.A. from College of the Holy Cross.

  • Anne Marie thoughtfully guides Sage on legal strategy, intellectual property, corporate governance, and more. She joined Sage as General Counsel in 2015, after serving as Senior Vice President, General Counsel and Secretary at Aegerion Pharmaceuticals. Previously, Anne Marie was a partner with Boston-based law firm Choate Hall & Stewart LLP (Choate), where she represented life science companies in structuring and negotiating strategic transactions such as joint ventures, collaborations, mergers and acquisitions and intellectual property. Prior to joining Choate, she was Senior Vice President, Business & Corporate Development, General Counsel at ViaCell, Inc., and Chief Corporate Counsel at Biogen.

    Anne Marie holds a B.S. in biology from Tufts University and a J.D. from the University of Notre Dame Law School.

  • Jim leads the Sage research team that has pioneered more decisive methods for making development decisions. He joined Sage in 2012 with more than 14 years of experience in neuroscience drug discovery and development. He most recently served as Director and Head of Neuroscience for the CNS and pain innovative medicine unit of AstraZeneca Pharmaceuticals in Sodertalje, Sweden, where he was responsible for leading preclinical research in neurology and pain control. Previously, Jim was Director and Head of the Neuroscience Department at AstraZeneca Pharmaceuticals in Wilmington, Del., where he led preclinical research in psychiatry and cognition. He has experience with discovery, translational science and early development in several areas of neuroscience research, including psychiatry, neurology, cognition, epilepsy and analgesia. Jim’s teams have delivered multiple candidate compounds into clinical development. He has authored more than 30 peer-reviewed research and review articles.

    Jim holds a B.A. in biology from the University of Delaware and a Ph.D. in neuroscience from Georgetown University. He was a post-doctoral fellow at Emory University Medical School.

  • With a background that includes both science and finance, Kimi has carefully crafted a financial strategy that has allowed Sage to remain a nimble, independent, and innovative biopharmaceutical company. She joined Sage as CFO in 2013, bringing financial and operating strength from her senior management experiences at established, and emerging, life science companies. Prior to joining Sage, Kimi served as Chief Operating Officer, North America, for Santhera Pharmaceuticals, and Vice President of Finance at Cyberkinetics Neurotechnology Systems. Previously, Kimi held roles of increasing responsibility at Millennium Pharmaceuticals and Biogen. She also worked as a business assurance manager at PricewaterhouseCoopers LLP and began her career in chemistry-related positions at various Boston-based companies.

    Kimi holds a B.A. in chemistry from Drew University and an M.B.A. from Northeastern University. She earned her CPA in Massachusetts.

  • Steve Kanes is responsible for Sage’s clinical-stage programs and is the company’s primary liaison with the investigator community. His experience as a practicing psychiatrist helped him advance through increasing positions of responsibility at AstraZeneca Pharmaceuticals, culminating in his role as the Executive Director/Therapeutic Area Clinical Director for the inflammation, neuroscience and respiratory GMED division at the company. He is an adjunct assistant professor of psychiatry at the University of Pennsylvania School of Medicine and has authored or co-authored more than 30 peer-reviewed publications. He serves as an ad hoc reviewer for the journals Neuropsychopharmacology, American Journal of Medical Genetics and Biological Psychiatry.

    Steve received his B.A. from the University of Pennsylvania and both his Ph.D. and M.D. from State University of New York, Stony Brook. He completed his psychiatry residency at Yale-New Haven Medical Center and postdoctoral fellowship at the University of Pennsylvania.

  • Erin built and fosters the high-performing culture that has made Sage a success, nurturing it as the Company has grown from a small startup to a major player in biotech and CNS. She joined Sage in 2014 with more than 20 years of experience in developing human resources strategies and programs. Previously, Erin served as Executive Director, Human Resources, Global Commercialization at Bristol-Myers Squibb (BMS). In 2009, Erin relocated to Paris where she was the HR Director for European Markets at BMS, serving as the strategic business partner responsible for all aspects of HR across multiple European commercial, R&D and corporate functions. This followed her tenure at Adnexus, where she was the Vice President, Human Resources and a member of the executive leadership team responsible for driving strategy and ensuring a successful integration of Adnexus into BMS. Earlier, as Vice President of Human Resources at Therion Biologics Corporation, she was instrumental in defining and creating the company’s culture and HR infrastructure. Prior to Therion, she was the Director of Human Resources for ViaCell; Human Resources Business Partner at Genzyme Corporation; and, was a Founder/Partner of Outsourcing Solutions, Inc., a human resource consulting firm.

    Erin earned her B.S. in Business Administration from Northeastern University.

  • Al leads teams in early-stage discovery up through non-clinical development, identifying new drug candidates for advancement into clinical research. Al joined Sage as CSO in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation. Earlier, as Senior Director and Head of the Neuroscience Discovery Chemistry Department of Wyeth Research, Al led a group that successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications. He has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 50 patents and patent applications.

    Al holds a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

  • Amy leads our interactions with regulatory bodies, ensures our submissions meet the highest standards, and weighs in on clinical study design quality issues and on timing, logistics and operational recommendations for product development. Amy came to Sage with extensive expertise in regulatory affairs and quality assurance over more than 20 years in the biotech and life science industries, including more than 15 years in executive management. As Vice President, Regulatory Affairs at Sunovion Pharmaceuticals (previously Sepracor), she led regulatory strategy regarding clinical development of CNS compounds and later managed development and commercial regulatory activities for all drug, biologic, and combination device products at the company’s Marlborough campus. Prior to Sunovion, Amy spent seven years leading the regulatory affairs function at Stryker Biotech, where she charted successful regulatory strategies for biologic orthopedic products and was an integral part of the quality team.

    Amy received her B.S. in biomedical engineering at Rensselaer Polytechnic Institute and her Ph.D. and M.S. in biomedical engineering at the University of Virginia. In 2014, Amy was named as one of the Boston Business Journal/Mass High Tech 2014 Women to Watch.

  • Heinrich leads the pharmaceutical development, manufacturing and supply chain teams at Sage, and is responsible for ensuring compliant, efficient and cost-effective production of Sage products. He joined Sage in 2015 as Senior Vice President, Technical Operations. Before joining Sage, Heinrich served as Vice President, Process Development & Manufacturing at Cubist, Inc., where he was responsible for developing manufacturing processes for new products, all CMC-related development, and for overseeing external manufacturing partners for clinical stage and commercial products. Prior to his 10-year tenure at Cubist, he held various positions in process development and manufacturing support at Hoffman-La Roche in Switzerland, New Jersey and Germany.

    Heinrich holds both a chemistry degree and a Ph.D. in biochemical engineering from the Braunschweig University of Technology, Germany.

Board of Directors

  • Kevin is a proven operational leader with more than 25 years of experience building and operating leading biotech companies. Kevin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of the firm’s portfolio companies as well as actively identifying and evaluating new investments. Prior to Third Rock Ventures, Kevin was Chief Operating Officer and Chief Financial Officer at Millennium Pharmaceuticals, where he led key roles in raising billions of dollars in capital through strategic alliances and public financing and driving growth through company expansion and mergers and acquisitions. Earlier in his career, he served in various executive roles at Millennium BioTherapeutics, Biogen and Digital Equipment Corporation. He is currently a Board Member of Alnylam Pharmaceuticals.

    Kevin holds a M.S. in Corporate Finance from Boston College and a B.A. in Mathematics and Business from Colby College.

  • Jeff joined Sage as CEO in 2013 and has more than 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the CNS field. Before joining the Sage team, Jeff served as President of the Regenerative Medicine Division of Shire plc and previously as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Prior to Shire, he served as the Executive Vice President of ISIS Pharmaceuticals, as the Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc. and in senior-level positions at Upjohn Laboratories. Jeff founded AVAX Technologies, where he served as CEO and President, and SCEPTOR Industries, where he served as Chairman, President and Chief Technology Officer. Earlier in his career, he served as Independent Director at Cara Therapeutics, Inc. and Director of AVAX Technologies. Jeff is a member of the board for Decibel Therapeutics, Generation Bio and Karuna Pharmaceuticals. He has published more than 70 scientific papers and chapters, authored more than 100 books, scientific articles and abstracts, and has received numerous awards.

    Jeff received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard and then served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School.

  • Liz Barrett is the President & Chief Executive Officer of UroGen, a clinical stage biopharmaceutical company focused on urological-oncology diseases.

    Prior to joining UroGen, Ms. Barrett was the Chief Executive Officer of Oncology at Novartis, where she oversaw more than 10,000 associates in 85 countries. Ms. Barrett was also a member of the Executive Committee of Novartis.

    Ms. Barrett was previously Global President of Oncology at Pfizer, Inc. While at Pfizer, Ms. Barrett held numerous leadership positions, including President of Global Innovative Pharma for Europe, President of the Specialty Care business unit for North America, and President of United States Oncology. Prior to Pfizer, she was Vice President and General Manager, Oncology business unit at Cephalon Inc. from 2006 to 2009, where she built the unit from scratch and launched Cephalon into Oncology. Ms. Barrett also worked at Johnson & Johnson across their consumer, diagnostics and biopharma sectors. Ms. Barrett started her career at Kraft Foods Group Inc. in 1984.

    Ms. Barrett holds a Bachelor of Science from the University of Louisiana and a Master of Business Administration from Saint Joseph’s University.

  • Michael currently serves as president and chief executive officer of Medgenics, Inc. Prior to joining Medgenics, he served as president of specialty pharmaceuticals at Shire plc, a global specialty pharmaceutical company he first joined in 2005 as executive vice-president of global therapeutic business units and portfolio management. Previously, Michael also served as a growth capital provider and president of the life sciences group for Safeguard Scientifics, Inc., where he served as chairman and chief executive officer of Clarient, Inc., and chairman of Laureate Pharma, Inc. In addition, Michael has held senior positions in product development and commercialization at AstraMerck and AstraZeneca.

    Michael received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He also serves on the board of directors at Vanda Pharmaceuticals Inc. and Pennsylvania BIO, and serves as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia.

  • Jim serves as Senior Vice President and Chief Financial Officer of Alkermes. Prior to joining Alkermes in 1998, Jim was a Vice President in charge of the East Coast Life Sciences Practice at Robertson Stephens & Company. He also worked in healthcare investment banking at Morgan Stanley & Company and spent a year teaching secondary school at the Royal Shrewsbury School in the U.K., as the Harvard College Fellow. Jim served on the Board of Directors of GPC Biotech AG from June 2004 to June 2009 and was a national director of the Association of Bioscience Financial Officers. He also serves as a Trustee and Treasurer of St. Paul’s School. Jim received a Bachelor of Arts degree in government from Harvard College and a Master of Business Administration from Harvard Graduate School of Business Administration.

  • Geno was most recently President of Intrexon, a leader in synthetic biology, from June 1, 2016 to March 2017. As President, Mr. Germano led Intrexon’s management team and commercialization efforts utilizing the Company’s technology platform for biologically-based solutions across a broad range of industries including Health, Consumer, Energy, Environment and Food.

    Mr. Germano has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value. He held numerous leadership roles in multiple therapeutic categories and global markets at Pfizer, Wyeth and Johnson & Johnson. Prior to joining Intrexon, he was Group President of Pfizer’s Global Innovative Pharma Business, where he consistently grew this $14 billion global business and guided the development of an extensive portfolio of late-stage development candidates in the cardiovascular, metabolic disease, neuroscience, inflammation, immunology, and rare diseases therapeutic areas. Mr. Germano was also Co-Chair of the Portfolio Strategy and Investment Committee focused on maximizing the return on research and development investment across the Pfizer portfolio. Previously, Mr. Germano served as President and General Manager of Pfizer’s Specialty Care and Oncology business units where he led commercial, medical, and post proof-of-concept pipeline strategy and development across global markets, as well as held responsibility for driving P&L growth and pipeline value through disciplined portfolio management. In addition, while in this role he directed the integration of Wyeth and Pfizer Specialty Care and Vaccines Businesses and developed top talent within the organization focusing on the leadership team.

    Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals including President of Wyeth U.S., where he was responsible for delivery of operational results across four business units, as well as President of its Global Pharmaceutical and Women’s Healthcare Business. He has been a member of the Group of Fifty (G50) and served on the Board of the Biotechnology Innovation Organization, where he was a member of the Executive Committee and Chaired the International Committee. He continues to serve on the Advisory Board of the Healthcare Businesswomen’s Association and as a Trustee of the Albany College of Pharmacy where he received his Bachelor of Science degree in Pharmacy. Geno was formerly a Director of Zoetis Inc., and is currently a director of Bioverativ.

  • George is currently President and Head of Corporate Development and Strategy at GRAIL, a health-care company focused on the early detection of cancer. Prior to joining GRAIL in 2018, he was Executive Vice President of Business Development for Celgene Corporation, where during his 9-year tenure he was responsible for a full array of business development including in-licensing, strategic collaborations, M&A, out-licensing and alliance management.

    During his tenure at Celgene, George developed new models for corporate collaborations, and led a business development effort that saw Celgene become “Partner of Choice” according to Boston Consulting Group Survey data.

    George was previously Vice President of Business Development, Licensing and Strategy at Novartis. Prior to Novartis, he was Vice President of R&D Business Development at Elan and Vice President of Corporate Development at Schwarz Pharma, where he led CNS acquisitions worldwide.

    George holds a B.A. in Biology from the University of Virginia, a Ph.D. in Genetics from the University of Wisconsin-Madison, and he conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder.

  • Asha currently serves as chief medical officer at Intel Corporation where she guides its healthcare investment strategy and provides clinical and business leadership to Intel’s broad spectrum of healthcare programs. She served as co-principal investigator on four clinical studies that demonstrated the value of Intel technologies in the areas of oncology and preventative cardiology. Asha’s work played a seminal role in the development of brain MRI for stroke diagnosis in addition to multiple interventional cardiology tools in use today. Before joining Intel, she was vice president at New Leaf Venture Partners, guiding its investments in the medical device sector. Earlier, Asha created and led several new therapy programs at Medtronic. Now, and throughout her career, she maintains an active clinical practice at the Stanford VA emergency department. She is the inventor on numerous patents and is published in several textbooks and peer-reviewed journals.

    Asha holds an M.D. and Ph.D. in neuroscience from the University of Colorado and completed internal medicine residency and Biodesign Innovation Fellowship programs at Stanford University.

  • Steve has had a distinguished 40-year career in neuroscience, particularly in molecular neuropharmacology and CNS drug discovery and development. Steve is the scientific co-founder of Sage Therapeutics and served as its interim start-up Head of R&D. He is also the co-founder of Voyager Therapeutics, a CNS gene therapy company, and served as its President and CEO. Steve is the CEO and Chairman of Karuna Pharmaceuticals, a company developing novel treatments for psychosis, cognition, and pain. Steve is the former Director of the Appel Alzheimer Disease Research Institute at Weill Cornell Medical College and is currently an Adjunct Professor of Psychiatry at Washington University of St. Louis School of Medicine. Prior to his appointments at Weill Cornell and Washington University, Steve spent 17-years at Eli Lilly and Company, during which time he held several key leadership roles, including Vice President of Neuroscience and Clinical Investigation, Executive Vice President for Science and Technology, and President of the Lilly Research Laboratories, where he was responsible for the company’s overall research and development efforts. Prior to Lilly, Steve spent 18 years at NIH as a Laboratory / Branch Chief and as the Scientific Director of the National Institute of Mental Health.

    Steve has been the recipient of many awards and honors and has served on numerous committees and advisory boards. He has also authored or co-authored more than 550 papers and book chapters. Steve is an elected fellow of the American Association for the Advancement of Science and a member of the National Academy of Medicine of the National Academy of Sciences. He is also an elected Fellow Emeritus of the American College of Neuropsychopharmacology (ACNP) and served as ACNP President (1999). Steve is also currently on the board of directors or is a trustee of several organizations, including serving as Chairman of the Board of the Foundation for the NIH (FNIH) and as a Director of Alnylam Pharmaceuticals, Sage Therapeutics, Voyager Therapeutics and Karuna Pharmaceuticals. Steve has also served as a member of the National Institute of General Medical Sciences (NIGMS) and the National Institute of Mental Health Advisory Councils and was appointed by the Secretary of the Department of Health and Human Services (HHS) as a member of the Advisory Committee to the Director of the NIH from 2001-2006 as well as to the Science Board of the FDA (2012-2014).

    Steve received his B.A. in Biology and Psychology from Tulane University, and his M.S. and M.D. degrees from the Tulane University School of Medicine.